HK21595A - Use of 1-(3-dimethyl-amino)propyl)-1-phenylphthalenes for the treatment of cerebrovascular disorders - Google Patents

Use of 1-(3-dimethyl-amino)propyl)-1-phenylphthalenes for the treatment of cerebrovascular disorders

Info

Publication number
HK21595A
HK21595A HK21595A HK21595A HK21595A HK 21595 A HK21595 A HK 21595A HK 21595 A HK21595 A HK 21595A HK 21595 A HK21595 A HK 21595A HK 21595 A HK21595 A HK 21595A
Authority
HK
Hong Kong
Prior art keywords
propyl
treatment
cerebrovascular disorders
phenylphthalenes
dimethyl
Prior art date
Application number
HK21595A
Other languages
English (en)
Inventor
Yoshiaki Tanaka
Naomi Kobayashi
Tadashi Kurimoto
Yugo Ikeda
Original Assignee
Lundbeck & Co As H
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26066379&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HK21595(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lundbeck & Co As H filed Critical Lundbeck & Co As H
Publication of HK21595A publication Critical patent/HK21595A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HK21595A 1990-09-06 1995-02-16 Use of 1-(3-dimethyl-amino)propyl)-1-phenylphthalenes for the treatment of cerebrovascular disorders HK21595A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DK213290A DK213290D0 (da) 1990-09-06 1990-09-06 Treatment of cerebrovascular disorders
SG165594A SG165594G (en) 1990-09-06 1994-11-16 1-[3-(dimethylamino)propyl]-1-phenylphthalenes for the treatment of cerebrovascular disorders

Publications (1)

Publication Number Publication Date
HK21595A true HK21595A (en) 1995-02-24

Family

ID=26066379

Family Applications (1)

Application Number Title Priority Date Filing Date
HK21595A HK21595A (en) 1990-09-06 1995-02-16 Use of 1-(3-dimethyl-amino)propyl)-1-phenylphthalenes for the treatment of cerebrovascular disorders

Country Status (14)

Country Link
EP (1) EP0474580B1 (ko)
JP (1) JPH085787B2 (ko)
KR (1) KR970002246B1 (ko)
AT (1) ATE112166T1 (ko)
AU (1) AU644204B2 (ko)
CA (1) CA2049368C (ko)
DE (1) DE69104314T2 (ko)
DK (2) DK213290D0 (ko)
HK (1) HK21595A (ko)
IE (1) IE72160B1 (ko)
IL (1) IL98968A (ko)
NZ (1) NZ239437A (ko)
SG (1) SG165594G (ko)
ZA (1) ZA916187B (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA001728B1 (ru) * 1997-07-08 2001-08-27 Х.Лундбекк А/С Способ получения циталопрама
JP4674339B2 (ja) * 1998-08-07 2011-04-20 三菱化学株式会社 脳損傷の予防・治療剤
AU746665B2 (en) * 1998-10-20 2002-05-02 H. Lundbeck A/S Method for the preparation of citalopram
BR9916955A (pt) 1998-12-23 2001-09-11 Lundbeck & Co As H Método para preparação de 5-cianoftalida
PL198024B1 (pl) 1999-04-14 2008-05-30 Lundbeck & Co As H Sposób wytwarzania citalopramu, związki pośrednie i ich zastosowanie do wytwarzania citalopramu
ITMI991581A1 (it) * 1999-06-25 2001-01-15 Lundbeck & Co As H Metodo per la preparazione di citalopram
AR021155A1 (es) * 1999-07-08 2002-06-12 Lundbeck & Co As H Tratamiento de desordenes neuroticos
GB2357762B (en) 2000-03-13 2002-01-30 Lundbeck & Co As H Crystalline base of citalopram
BG64901B1 (bg) * 2000-05-29 2006-08-31 H. Lundbeck A/S Метод за получаване на циталопрам
FI20011622A (fi) 2000-08-18 2002-02-19 Lundbeck & Co As H Menetelmä sitalopraamin valmistamiseksi
DK1181713T3 (da) * 2000-12-22 2005-01-31 Lundbeck & Co As H Fremgangsmåde til fremstilling af rent citalopram
BG65515B1 (bg) * 2002-07-26 2008-10-31 H. Lundbeck A/S Метод за получаване на 5-цианофталид
CA2548917C (en) 2003-12-11 2014-09-23 Sepracor Inc. Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression
TW200812993A (en) * 2006-05-02 2008-03-16 Lundbeck & Co As H New uses of escitalopram
DE102007051090A1 (de) 2007-06-28 2009-01-08 Charité - Universitätsmedizin Berlin SSRI zur Behandlung neuronaler Krankheiten
EP2008653A1 (de) 2007-06-28 2008-12-31 Charité-Universitätsmedizin Berlin Serotonerge Verbindungen zur Behandlung neuronaler Krankheiten
CN104005415B (zh) * 2014-02-18 2015-12-02 中铁十六局集团北京轨道交通工程建设有限公司 微风化花岗岩中地下连续墙的高效成槽施工方法
CN106871753B (zh) * 2017-01-04 2018-10-16 中铁隧道集团有限公司 一种用于提高水平岩层隧道成型的装药方法

Also Published As

Publication number Publication date
EP0474580A2 (en) 1992-03-11
JPH04244024A (ja) 1992-09-01
DK0474580T3 (da) 1995-04-03
ZA916187B (en) 1992-04-29
AU8259491A (en) 1992-03-12
EP0474580A3 (en) 1992-06-03
NZ239437A (en) 1997-02-24
KR920005983A (ko) 1992-04-27
IL98968A (en) 1996-06-18
EP0474580B1 (en) 1994-09-28
CA2049368A1 (en) 1992-03-07
IL98968A0 (en) 1992-07-15
SG165594G (en) 1995-05-12
IE912682A1 (en) 1992-03-11
IE72160B1 (en) 1997-03-26
CA2049368C (en) 2001-10-23
AU644204B2 (en) 1993-12-02
KR970002246B1 (ko) 1997-02-26
DE69104314D1 (de) 1994-11-03
JPH085787B2 (ja) 1996-01-24
DE69104314T2 (de) 1995-02-16
ATE112166T1 (de) 1994-10-15
DK213290D0 (da) 1990-09-06

Similar Documents

Publication Publication Date Title
HK21595A (en) Use of 1-(3-dimethyl-amino)propyl)-1-phenylphthalenes for the treatment of cerebrovascular disorders
GB2256196B (en) Heterocyclic derivatives
KR0179054B1 (en) Heterocyclic-cyclic amine derivatives
EP0530505A3 (en) Hydantoin derivatives
GR3030798T3 (en) 2-(Piperidin-4-yl, pyridin-4-yl and tetrahydropyridin-4-yl)benzofuran-7-ol and carbamate derivatives, their preparation and their use as acetylcholinesterase inhibitors.
GB9113628D0 (en) Heterocyclic derivatives
ZA89389B (en) Use of 1,4-disubstituted-piperidinyl compounds in the manufacture of a medicament for the treatment of insomnia
DE69018726D1 (de) Cumarinderivate, ihre Herstellung und ihre Verwendung zur Behandlung von zerebrovaskulären Störungen.
NO934741L (no) Fremgangsmåte for minimalisering og kontroll av ischemiske og reperfusjonsskade
ES8602723A1 (es) Un procedimiento para la preparacion de nuevas n-bencil-propilaminas sustituidas.
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems
ZA88639B (en) Substituted 3-phenyl-7h-thiazolo(3,2-b)(1,2,4)triazin-7-ones,a process for the preparation thereof,medicaments containing same and the use thereof,and also some intermediates formed in the preparation of the compounds mentioned
WO2000009099A3 (en) Treatment of vasodilatory headache
TH2277A (th) สารประกอบ
RO95572A2 (ro) Procedeu pentru prepararea unor derivati de 1,3-oxazolidin-2-ona
JO1720B1 (en) Heterocyclic derivatives

Legal Events

Date Code Title Description
PF Patent in force
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20100816